Cell Therapeutics News

After re-reading all of the Biotech Stock Mailbag columns published in 2009, it's quite clear I wrote often about Cell Therapeutics and Hemispherx Biopharma .

STOCK MARKETING INC PRESENTS : AGR Tools, Inc., Acacia Research Corp., Zagg, Inc., Santarus, Inc., Cell Therapeutics, Inc., Ballard Power Systems, Inc.

Cell Therapeutics, Inc. announced today its support of the Pharmaceutical Research Manufacturers of America's "Code on Interactions with Healthcare Professionals, revised July 2008" . Adherence to the Code is voluntary for commercial biotechnology and pharmaceutical companies.

Cell Therapeutics, Inc. announced today that the European Medicines Agency has granted pixantrone orphan drug designation for the treatment of DLBCL which accounts for about 80% of aggressive non-Hodgkin's lymphoma.

Dallas, TX - Cell Therapeutics, Inc. surged 8.57% to $1.14 on 47.57 million shares.

Cell Therapeutics , the Seattle-based developer of pixantrone for non-Hodgkin's lymphoma, said today that the experimental treatment will be reviewed by an FDA advisory panel on February 10.

Cell Therapeutics, Inc. announced today that on February 10, 2010 the U.S. Food and Drug Administration's Oncologic Drugs Advisory Committee will review the New Drug Application for pixantrone for the treatment of relapsed/refractory aggressive non-Hodgkin's lymphoma .

It's the most wonderful time of the year. That's right -- it's that time when everyone on Wall Street comes out to make their market predictions for the year ahead.

Cell Therapeutics will be bringing its lymphoma drug pixantrone in front of a Food and Drug Administration advisory committee meeting in February, according to a newly published notice in the Federal Register.

CEO Jim Bianco is on the road again -- and he has Rodman & Renshaw bankers in tow.

Cell Therapeutics, Inc. announced today that Ruth Pettengell, M.D. of St. George's Hospital, University of London during a session at the 2009 American Society of Hematology Annual Meeting updated results from the pivotal phase III EXTEND clinical trial of pixantrone in relapsed or refractory, aggressive non-Hodgkin's lymphoma patients who have ...

BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors has Healthcare stock news and updates to its calendar database of Clinical Trials and upcoming FDA approvals & decisions.

Cell Therapeutics, Inc. announced today that its new class of platinum-based anti-tumor compounds, termed bis-platinates, demonstrated a stronger anti-tumor potency and activity compared to currently available platinum-based compounds as well as the ability to overcome cisplatin-resistance in cancer cell lines.

DAILY's rigid UHF tag is specially designed for Industrial Applications, since it is extremely resistant to harsh environment, including metallic and moist conditions.

November 20th, 2009 -Wondershare Software Co., Ltd, the world leading consuming software provider, announces a new product release----Wondershare Spyware Removal on its system utility official website .

A federal appeals court has ruled that Cell Therapeutics can pursue a claim for nearly $23 million against a former consultant that advised it to market a drug off-label, adding a whole new wrinkle to whistleblower lawsuits.

Seattle biotechnology firm Cell Therapeutics Inc. can pursue claims for nearly $23 million against a former consultant, a federal appeals court ruled Wednesday.

Christmas and Hanukah came early this year for executives and directors at Cell Therapeutics .

Cell Therapeutics Inc. filed Quarterly Report for the period ended 2009-09-30. Cell Therapeutic developing acquiring and commercializing novel treatments for cancer.

A few fun tidbits for a Fall Friday: Uh-oh, Oculus Innovative Sciences ! Where is all that pent-up demand for the diluted bleach that the company peddles as Microcyn? The company announced results for the fiscal second quarter last night, with Microcyn sales of $1.4 million, down 13% sequentially.